Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.

In conclusion, GLP-1 receptor agonists and DPP-4 inhibitors appear to hold promise in patients with NAFLD but larger controlled studies with histological and clinical endpoints are needed to evaluate their effects in this population. PMID: 25412688 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25412688?dopt=Abstract

Source: Current Vascular Pharmacology - November 20, 2014 Category: Drugs & Pharmacology Authors: Nakouti T, Karagiannis AK, Tziomalos K, Cholongitas E Tags: Curr Vasc Pharmacol Source Type: research